Navigation Links
ReBuilder Medical Technologies, Inc. 4th Quarter Sales Increase 100% Exceeding Projections
Date:12/21/2007

Expected Release of Several MRSA Related Products in our Molluscum Line in the First Quarter of 2008

CHARLES TOWN, W.Va., Dec. 21 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), developers of state of the art electronic devices for diabetic peripheral neuropathy, Molluscum Contagiosum, and MRSA, announces 4th quarter sales projections up 100% over last year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

"We are projecting that sales will have doubled for the 4th quarter over last year; achieving the $1 million mark in sales for the quarter. Final sales numbers will be reported in January 2008," said Daena Carter, CFO of RBRM.

"With the expected release of several MRSA related products in our Molluscum line in the first quarter of 2008 and the expected release of a unique peripheral neuropathy diagnostic device in the second quarter of 2008; we expect to continue our pattern of growth," according to David B. Phillips, Ph.D., CEO of RBRM, and inventor of the company's unique products.

For more information visit: http://www.rebuildermedical.com, http://www.molluscum.com.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition
'/>"/>

SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
2. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
3. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
4. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
5. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
6. ReBuilder Medical Technologies, Inc. Announces Agreement with Internet Marketer Helio Health; Anticipates 12% Additional Profit
7. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
8. ReBuilder Medical Technologies, Inc. Increases Manufacturing Space to Meet Demand
9. ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support
10. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
11. ReBuilder Medical Technologies, Inc. Announces Record Sales Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... -- The University HealthSystem Consortium (UHC) recognized 10 ... in UHC,s Supply Chain Optimization Program. The leaders ... best practices in supply chain program participation. ... winners were determined using 2008 data and based ... and use of UHC resources. ,, Characteristics of ...
(Date:12/6/2009)... in Cambridge have discovered that the loss of a key ... is the first study to show that this kind of ... in Nature . , The study, led by Dr ... Hurles from the Wellcome Trust Sanger Institute, looked at 300 ... entire genome looking for types of mutation known as copy ...
(Date:12/6/2009)... ORLEANS, Dec. 6 Onyx Pharmaceuticals, Inc. ... data from the pivotal Phase 2b 003-A1 study, ... is well-tolerated in heavily pre-treated relapsed and refractory ... at the ASH/ASCO Joint Symposium at the 51st ... (ASH) in New Orleans. Enrollment in this trial ...
(Date:12/6/2009)... Sleep Disorders information and Treatment site www.sleeping-with-a-sleeping-disorder.com ... problems with herbal or natural sleep aids from ... remedies for a good cause. The submissions will ... Sleep Aids ,Encyclopedia, by YOU, to be sold ... site will donate 100% of the proceeds ,from ...
(Date:12/5/2009)... been significant scientific advances in the field of blood ... understanding of how certain diseases progress in order to ... best care. Research presented today at the 51st Annual ... induction therapies for managing multiple myeloma, the importance of ...
Breaking Medicine News(10 mins):Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... N.J., Feb. 19 Wyeth (NYSE: WYE ),announced ... Circuit Court,for Baltimore City in Baltimore, Maryland, has granted ... et al. v. Sigma Aldrich, Inc.,et al -- an ... thimerosal-containing vaccines caused him to become autistic., Previously, ...
... schizophrenia also tend to occur in their healthy siblings, ... the Neuroscience of Mental Disorders at Washington University School ... in the brain,s thalamus. , The researchers performed brain ... non-affected siblings and compared the scans with those of ...
... obese have lower concentrations of prostate-specific antigen (PSA) in ... new study led by Duke University Medical Center researchers. ... found in obese and overweight men with prostate cancer ... for heavier patients, and to encourage those patients to ...
... Chicago, CHICAGO, Feb. 19 The following release ... The Chicago Dental Society (CDS) recently polled more than ... adults seeking,braces, and how the current presidential candidates, smiles ... Meeting, one of the largest,displays of dental products in ...
... as a Snack or Condiment is a Healthy Choice ... ... February marks a food,quandary with observances of both Heart-Healthy Month and National ... outside traditional meal times; unfortunately, their snack,choices are not always healthy ones. ...
... -- Researchers and clinicians from the Indiana University School ... distinction between lab and clinic as they debut the ... care model they developed and extensively tested over the ... care is on two groups -- patients with cognitive ...
Other Medicine News:Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 3Health News:Siblings of schizophrenia patients display subtle shape abnormalities in brain 2Health News:Overweight and obese men have lower PSA values, even before they get prostate cancer 2Health News:New Guacamole 100-Calorie Packs - The Solution for Clashing February Holidays 2Health News:Merging discovery with therapy: Second generation memory care debuts 2Health News:Merging discovery with therapy: Second generation memory care debuts 3
(Date:12/4/2009)... AstraZeneca (NYSE: AZN ) today announced ... approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets ... Major Depressive Disorder (MDD). SEROQUEL XR is the only ... treat both major depressive disorder as adjunctive therapy and ...
(Date:12/3/2009)... YORK, Dec. 3 Guidepoint Global, LLC , a ... Sleep Apnea Tracker, a monthly longitudinal data release that monitors ... Apnea market. ,, The Sleep Apnea Tracker captures actual ... in the United States from 15 different equipment providers going ...
(Date:12/3/2009)... ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. ... the signing of an agreement to provide extended ... next-generation sequencing projects performed at Ambry. ... Kammesheidt PhD, Ambry,s CSO said, "Our team at ...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 1Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 2Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 3Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 4Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 5Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 6Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 7Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 8Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 9Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 10Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 11Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 12Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 13Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 14Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 15Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 16Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 17Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 18Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 19Sanofi aventis Announces Second Quarter 2009 Results 13244 1Sanofi aventis Announces Second Quarter 2009 Results 13244 2Sanofi aventis Announces Second Quarter 2009 Results 13244 3Sanofi aventis Announces Second Quarter 2009 Results 13244 4Sanofi aventis Announces Second Quarter 2009 Results 13244 5Sanofi aventis Announces Second Quarter 2009 Results 13244 6Sanofi aventis Announces Second Quarter 2009 Results 13244 7Sanofi aventis Announces Second Quarter 2009 Results 13244 8Sanofi aventis Announces Second Quarter 2009 Results 13244 9Sanofi aventis Announces Second Quarter 2009 Results 13244 10Sanofi aventis Announces Second Quarter 2009 Results 13244 11Sanofi aventis Announces Second Quarter 2009 Results 13244 12Sanofi aventis Announces Second Quarter 2009 Results 13244 13Sanofi aventis Announces Second Quarter 2009 Results 13244 14Sanofi aventis Announces Second Quarter 2009 Results 13244 15Sanofi aventis Announces Second Quarter 2009 Results 13244 16Sanofi aventis Announces Second Quarter 2009 Results 13244 17Sanofi aventis Announces Second Quarter 2009 Results 13244 18Sanofi aventis Announces Second Quarter 2009 Results 13244 19Sanofi aventis Announces Second Quarter 2009 Results 13244 20Sanofi aventis Announces Second Quarter 2009 Results 13244 21Sanofi aventis Announces Second Quarter 2009 Results 13244 22Sanofi aventis Announces Second Quarter 2009 Results 13244 23Sanofi aventis Announces Second Quarter 2009 Results 13244 24Sanofi aventis Announces Second Quarter 2009 Results 13244 25Sanofi aventis Announces Second Quarter 2009 Results 13244 26Sanofi aventis Announces Second Quarter 2009 Results 13244 27Narconon Graduate Delivers Drug Education in Florida 53033 1Narconon Graduate Delivers Drug Education in Florida 53033 2
... Pa. and LYON, France, Aug. 1 Sanofi,Pasteur, ... vaccine (Fluzone(R), Influenza Virus Vaccine) in the United,States ... doses of influenza,vaccine began shipping this week following ... Food and Drug Administration (FDA) on,July 14, 2008., ...
... CLL Meets ... Primary Endpoint, COPENHAGEN, ... GSK) announced today positive top-line,results from an interim analysis of the ... chronic lymphocytic,leukemia (CLL) patients with high unmet medical need. At the ...
Other Medicine Technology:Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 2Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 3Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 4Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 5Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 2Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 3Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 4Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 5Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 6
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
10 L, Stacked Rack, 96 tips/rack 5 racks/stack, clear Recommended for 2, 5, 10 L pipettes....
... been designed to optimize the accuracy and ... tip products is widely recognized by customers ... been extended over the years and now ... special tips including filter tips, certified pure ...
... HerpeSelect® 2 ELISA IgG test is intended ... human IgG class antibodies to HSV-2 in ... 1 ELISA IgG, the test is indicated ... for aiding in the presumptive,diagnosis of HSV ...
Medicine Products: